Articles for tag: Investing, Pre-Market, Stocks, US Markets

March 6, 2025

Ron Finklestien

Evaluating the Prospects of Investing in Kroger or Albertsons During Current Market Fluctuations

The Impact of Inflation Talks on Kroger and Albertsons Stocks On Thursday, markets faced a tumultuous day, as the S&P 500 and Nasdaq dropped over 2%. The decline stemmed from ongoing tariff discussions in the U.S., which raised concerns about the possibility of rising inflation. In this climate, Kroger KR and Albertsons ACI have proven resilient, hovering near their 52-week highs. These stocks are increasingly viewed as defensive plays amidst recent market fluctuations. Typically, during economic downturns, investors gravitate towards companies providing essential goods or services, making Kroger and Albertsons particularly attractive as two of the largest grocery retailers. Year-to-Date

November 21, 2024

Ron Finklestien

Sociedad Quimica Reports Below-Expected Earnings and Revenues for Q3

Sociedad Quimica y Minera S.A. Posts Disappointing Q3 Earnings Key Insights from SQM’s Third Quarter SQM earnings per share in Q3 was 46 cents, far below the Zacks estimate of 64 cents. SQM shares have lost 23.6% in the past year, compared to a 13.1% decline in the Fertilizers industry. Register now to see our 7 Best Stocks for the Next 30 Days report – free today! Sociedad Quimica y Minera de Chile S.A. (SQM) reported a profit of $131.4 million, or 46 cents per share, in the third quarter of 2024. This marks a significant decrease from the $479.4

September 9, 2024

Ron Finklestien

Investing in Dole and Pilgrim’s Pride: Savoring Stability Amid Market Chaos

September has a reputation for stirring up turbulence in the stock market, but amidst the chaos, Dole and Pilgrim’s Pride emerge as beacons of stability for investors seeking a safe haven in the stormy seas of volatility. Two Food Giants Weathering the Storm As market volatility heightens, Dole and Pilgrim’s Pride offer a glimmer of hope for investors seeking refuge. These two stalwarts in the consumer food industry, holding coveted spots on the Zacks Rank #1 (Strong Buy) list, are proving their mettle amidst the market mayhem. Dole: Nurturing Health, Growing Prosperity As a leading purveyor of fresh fruits including

May 22, 2024

Ron Finklestien

Reasons to Hold Envestnet (ENV) Stock in Your Portfolio

Shares of Envestnet, Inc. ENV have rallied 24.7% over the past year, outperforming the 19.6% growth of the industry it belongs to. The company has an impressive track record with respect to earnings surprise, having surpassed the Zacks Consensus Estimate in three of the trailing four quarters and matching once. The average beat is 9.4%. Its earnings for 2024 and 2025 are anticipated to grow 23.6% and 14.8%, respectively, year over year. Envestnet, Inc Price Envestnet, Inc price | Envestnet, Inc Quote Factors That Bode Well Envestnet’s robust recurring revenue is derived from asset and subscription models. It serves financial

May 20, 2024

Ron Finklestien

Deckers (DECK) to Post Q4 Earnings: What’s in the Cards?

Deckers Outdoor Corporation DECK is likely to register an increase in the top line when it reports fourth-quarter fiscal 2024 earnings results on May 23 after market close. The Zacks Consensus Estimate for revenues is pegged at $876.1 million, which indicates an improvement of 10.7% from the prior-year reported figure. The company, renowned for its design, marketing and distribution of footwear, apparel and accessories, is expected to observe a year-over-year decrease in its bottom line. Although the Zacks Consensus Estimate for fourth-quarter earnings per share has risen by 4.2% to $2.75 in the past 30 days, it still suggests a

May 16, 2024

Ron Finklestien

3 Drug Stocks to Watch on Raised 2024 Earnings & Sales Guidance

The first-quarter earnings season has come to an end for large drug and biotech companies, with Bayer reporting its results earlier this week. Per the Zacks classification, the pharma/biotech industry comes under the broader Medical sector, which comprises pharma/biotech as well as medical device companies. As of May 15, the Earnings Trends report showed that 87.9% of medical companies beat estimates for earnings and 72.4% beat the same for revenues. While earnings declined 24.3% year over year, revenues rose 6.9%. Concerns around the economy and inflation, Medicare drug price negotiations, the Federal Trade Commission’s scrutiny of M&A deals, regular pipeline setbacks and

May 16, 2024

Ron Finklestien

TreeHouse Foods (THS) Looks Resilient on Private-Label Strength

TreeHouse Foods, Inc. THS appears to be at the crossroads of promising opportunities and pressing challenges as it moves through 2024. Let’s delve deeper into the factors shaping the journey of this renowned private brand snacks and beverage company. Private-Label Strength and Market Dynamics One of TreeHouse Foods’ strategic advantages lies in its position within two thriving consumer trends. These include the growth of private-label groceries in North America and the ongoing shift in consumer preferences toward snacking. On its first-quarter 2024earnings call management highlighted consistent market share gains that private brands have achieved over the past two decades, indicating

May 10, 2024

Ron Finklestien

Reasons Why Investors Should Bet on RLI Stock Right Now

RLI Corp.’s RLI compelling product portfolio, rate increases, improved retention, higher premium receipts and sufficient liquidity make it worth adding to one’s portfolio. Optimistic Growth Projections The Zacks Consensus Estimate for RLI’s 2024 earnings per share indicates a year-over-year increase of 16.1% from the consensus estimate of 2023. The consensus estimate for revenues is pegged at $1.63 billion, implying a year-over-year improvement of 15.1% from the consensus mark of 2023. The consensus estimate for 2025 earnings per share indicates a year-over-year increase of 3.2% from the consensus estimate of 2024. The estimate for 2025 revenues is pinned at $1.75 billion,

May 9, 2024

Ron Finklestien

Nu Skin (NUS) Q1 Earnings Beat, Revenues Hurt by Currency Woes

Nu Skin Enterprises, Inc. NUS posted first-quarter 2024 results, wherein both the top and bottom lines declined year over year, and revenues missed the Zacks Consensus Estimate. Foreign currency headwinds had a greater-than-anticipated impact on revenues. However, the company’s diligent cost management efforts aided its bottom-line performance. Nu Skin is actively pursuing business transformation initiatives and advancing its integrated beauty, wellness and lifestyle ecosystem. While macroeconomic challenges hurt the affiliate and customer growth globally in the Nu Skin core business, the company saw notable gains in the Rhyz business. Key product launches such as ageLOC WellSpa iO, RenuSpa iO, and

May 7, 2024

Ron Finklestien

Shockwave Medical (SWAV) Q1 Earnings Beat, Revenues Rise Y/Y

Shockwave Medical, Inc. SWAV reported first-quarter 2024 earnings per share (EPS) of $1.44, which beat the Zacks Consensus Estimate of $1.04 by 38.46%. The company reported an EPS of $1.03 in the year-ago quarter. Revenue Details Revenues totaled $218.8 million, indicating an uptick of 36% from the prior-year period’s level. The top line also beat the Zacks Consensus Estimate by 5.66%. The growth was primarily driven by an increase in the purchase volume of products, both in the United States and abroad. Business Highlights In April 2024, Johnson & Johnson and Shockwave Medical announced that they have entered into a definitive